Special Issue "Botulinum Neurotoxins Antibody and Vaccine"
Deadline for manuscript submissions: closed (31 August 2017).
Interests: botulinum toxins; antibodies; monoclonal; sterigmatocystin antibodies
Interests: therapeutic antibodies; botulinum neurotoxin; intoxication therapy; immune responses
Botulinum neurotoxins (BoNTs) are true miracle protein molecules created by nature, which embody the biological functional beauty of yin and yang in the same structure. On the one hand, they are the most toxic substances known to human being, and are listed as one of the six highest-risk threat agents for bioterrorism in the USA, and they could cause botulism, a deadly human and animal disease if not treated timely. On the other hand, they are the key components of several widely used government approved medicines, such as Botox® and Myobloc®, for many clinical and cosmetic applications, with multi-billion dollar sales annually all over the world. To mitigate the potential risk of BoNTs, while making full use of their therapeutic powers for the ever-expanding list of human diseases, rationally-designed and applied antitoxins or vaccines seem to be the best option to accomplish this task. In this Special Issue of “Botulinum Neurotoxins Antibody and Vaccine”, the most up-to-date research and investigation on counter-measures for botulism are compiled, and the possible unwanted neutralizing antibody reaction issues in BoNT therapeutic targets are also discussed. Any format of antitoxin or vaccine for BoNT can be presented here, and a few reviews for the BoNT antibody or vaccine production will be selected as well.
Prof. Dr. Jianlong Lou
Prof. Dr. James D. Marks
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxins is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Botulinum neurotoxins (BoNTs)
- Bio-therat reduction
- Antibody Engineering
- Yeast display
- Phage display
- Cell Culture
- Molecular evolution
- Epitope mapping
- Animal model
- Mouse Recombinant